This is a renewal application for the Rutgers University CounterACT Research Center of Excellence, which isfocused on the discovery and development of drugs to treat poisoning from exposure to vesicants includingsulfur mustard, nitrogen mustard, and other mechanistically related chemical threat agents. The Centerconsists of three Research and Development Projects, each focused on a major vesicant target: the skin, thecornea and the lung. The overall goal of the Center is to identify specific targets in these tissues that can beused for therapeutic intervention. To accomplish this goal, mechanistic research using appropriate models forthe skin, cornea and lung is being performed by scientific experts in each of these areas. The Research andDevelopment Projects are supported by a Pharmacology and Drug Development Scientific Support Core and aPharmaceutics and Medicinal Chemistry Scientific Support Core, each consisting of investigators withconsiderable expertise in drug discovery, delivery and development. The Rutgers Center has discoveredseveral efficacious lead compounds and developed innovative formulations and delivery systems that increasepharmacological activity and improve pharmacokinetic profiles. Two lead compounds, one for mustard-induced ocular injury and another for mustard-induced lung injury, are FDA approved for other uses, and arebeing advanced for use as mustard countermeasures. IND-enabling studies have been completed on a leadcompound discovered to be effective against mustard-induced skin injury. The Rutgers CounterACT Centerhas established strategic corporate partnerships for advanced drug development with lead compounds andsupport by BARDA. A Research Education Core directed at students, postdoctoral trainees, technical staff,and new and established investigators has been highly successful and efforts will be expanded during the nextgrant period. Plans are to continue mechanistic research with the goal of identifying and developing secondgeneration drug products with improved effectiveness. Current drug leads will also be advanced in the FDAapproval process. It is anticipated that Center efforts will result in new drugs that will be in the advancedapproval process for treating vesicant poisoning in humans.
|Effective start/end date||9/15/06 → 6/30/21|
- National Institutes of Health (NIH)
Wounds and Injuries